View Clinical Trial (Medical Research Study)


RCT of an Acceptance-based Behavior Therapy for GAD - NCT00961493-02215(Clinical Trial 306370)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup

City:  Boston
State:  
MA
Zip Code: 02215
Conditions: Generalized Anxiety Disorder
Purpose: The purpose of this study is to determine whether acceptance-based behavior therapy for GAD results in greater symptom reduction and increased quality of life than applied relaxation.
Study summary:
Criteria: Inclusion Criteria: - principal diagnosis of GAD - at least moderate (4 on a scale from 0 to 8) on the ADIS Severity Scale for GAD symptoms - willing to maintain current psychotropic medication levels (and have been stabilized on any current medications for at least three months) and refrain from other psychosocial treatments for anxiety or mood problems during the course of therapy - fluent in English - 18 years or older Exclusion Criteria: - bipolar disorder - psychotic disorders - substance dependence - active suicidal intent - if anxious symptomatology is due to a medical/physical condition
Study is available at: Center for Anxiety and Related Disorders at Boston University
Boston, MA 02215
United States

Primary Contact:
Susan M Orsillo, Ph.D.
Email: sorsillo@suffolk.edu
Phone: 617-353-9610

Secondary Contact:
Lizabeth Roemer, Ph.D.
Email: lizabeth.roemer@umb.edu
Phone: 617-287-6358
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.

Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:
Only selected fields are shown, please use the link above to view all information about this clinical trial.